Stakeholder Perspectives on Enhancing Vaccine Manufacturing in Nigeria: A Quantitative Assessment of Influencing Factors

Download Article

DOI: 10.21522/TIJMD.2013.08.03.Art003

Authors : Longe Sunday Anthony, Abiodun Paul Olaiya, Rajendra Kumar BC, Eze, Chukwuemeka Francis

Abstract:

Nigeria has long experienced vaccine supply disruptions due to limited resources, inadequate infrastructure, and high dependence on imports—factors that have stalled the growth of local vaccine manufacturing. Achieving vaccine self-sufficiency and strengthening public health infrastructure require strategic investments, particularly in technology transfer. This study explores challenges and opportunities for enhancing vaccine production in Nigeria and provides recommendations for effective implementation. A descriptive cross-sectional survey was conducted using a structured questionnaire administered to 111 purposively selected stakeholders, representatives from academia, regulatory agencies, research institutions, development partners, and private industry. The questionnaire assessed six domains: regulatory environment, infrastructure, technical capacity, finance, human resources, and market dynamics. Data were analyzed using IBM SPSS version 25 with descriptive statistics and Spearman rank correlation. Out of the 111 participants, 57 responded to the question on key interventions to promote vaccine manufacturing. Among them, 68% identified technology-sharing with international manufacturers, government subsidies and tax incentives, and workforce development as top strategies. (Spearman’s rank) Strong positive correlations were found between local vaccine production capacity and regulatory support (ρ = 0.811, p < 0.01), infrastructure (ρ = 0.823, p < 0.01), access to finance (ρ = 0.844, p < 0.01), and market sustainability (ρ = 0.839, p < 0.01). Technical capacity (ρ = 0.693) and human resources (ρ = 0.637) showed moderate correlations. These findings highlight the multifaceted nature of barriers and enablers. Collaborative efforts among government, private sector, and international partners are essential to build sustainable, equitable vaccine manufacturing in Nigeria.

References:

[1].   Uzochukwu, B. S. C., et al., 2015, "Policy Barriers and Opportunities for Vaccine Production in Nigeria." Journal of Public Health Policy, 36(4), 471-487.

[2].   Nkengasong, J., Ndembi, N., & Moeti, M. 2021, Vaccine Manufacturing in Africa: Addressing the Barriers. The Lancet Global Health, 9(6), e758-e763.

[3].   Addressing the Barriers. The Lancet Global Health, 9(6), e758-e763.

[4].   AFDB (African Development Bank), 2023, Strengthening Africa’s Pharmaceutical and Vaccine Manufacturing Capacity. Retrieved from www.afdb.org

[5].   WHO (World Health Organization), 2021, The mRNA Vaccine Technology Transfer Hub. Retrieved from www.who.int

[6].   Clift, C., 2020, Understanding Technology Transfer in the Vaccine Industry. Vaccine Insights, 11(3), 301-317.

[7].   GAVI (Global Alliance for Vaccines and Immunization), 2023, Vaccine Supply Chain and Manufacturing Strategies. Retrieved from www.gavi.org

[8].   Kraus, M., Smith, D., & Alhassan, T., 2020, Evaluating Technology Transfer in African Vaccine Manufacturing. Journal of Global Health Policy, 32(2), 112-129.

[9].   AfDB (African Development Bank), 2023, Strengthening Africa’s Pharmaceutical and Vaccine Manufacturing Capacity. Retrieved from www.afdb.org

[10].  Okereke, E., & Ekeke, P., 2021, Policy Frameworks for Sustainable Vaccine Manufacturing in Nigeria. Journal of African Health Economics, 27(1), 45-62.

[11].  Chakraborty, T., & Singh, R., 2020, The Role of Technology Transfer in Vaccine Production: Lessons from India. International Journal of Vaccine Research, 18(4), 189-203.

[12].  World Health Organization (WHO), 2021, Local production and technology transfer to increase access to COVID-19 vaccines: Policy brief. https://www.who.int/publications/i/item/WHO-UHL-PHC-SPP-2021.01

[13].  Narayan, V., & Campbell, S., 2019, Healthcare Investments in Emerging Markets: The Role of Collaborative Agreements. Healthcare Finance Journal, 24(2), 195-210.

[14].  World Health Organization, 2021, Global Vaccine Manufacturing and Regulatory Frameworks. WHO Press.

[15].  Marston, N., & Morgan, G., 2020, "Capacity Constraints in Developing Countries' Health Sectors: A Study on Vaccine Production." Development Journal, 30(1), 113-130.

[16].  Rogers, E. M., 2003, Diffusion of Innovations (5th ed.). Free Press.

[17].  Kraus, M., Smith, D., & Alhassan, T., 2020, Evaluating Technology Transfer in African Vaccine Manufacturing. Journal of Global Health Policy, 32(2), 112-129.

[18].  Gavi, the Vaccine Alliance. 2022, Sustainable vaccine manufacturing in Africa: Gavi’s position paper. https://www.gavi.org

[19].  World Health Organization (WHO), 2023, Global Vaccine Market Report: Nigeria’s Standing in Local Production. WHO Publications.

[20].  Nigerian Ministry of Health, 2022, Policy Review on Nigeria’s Vaccine Production Capacity. Federal Ministry of Health Report.

[21].  GAVI, 2023, Nigeria Vaccine Investment Strategy: Funding and Developmental Progress. GAVI Reports on Vaccine Sustainability.

[22].  Chakrabarti, A., Banerjee, S., & Dey, S., 2022, "Growth of the Indian Vaccine Industry: Government Support and Market Expansion." Journal of Vaccine Research and Development, 15(2), 89-105.